Literature DB >> 7046975

Increased survival due to radioactive estradiol in mice with C3HBA or BW 10232 tumors.

B Thysen, G Rettura, J Padawer, M Gatz, S M Levenson, E Seifter.   

Abstract

The influence of progesterone and estradiol labeled with tritium was studied in mice inoculated with transplantable mammary adenocarcinomas C3HBA or BW 10232. Tumor size, tumor growth rate, and host survival were measured. Radioactive [3H]estradiol administration increased survival time and inhibited tumor growth in mice inoculated with these tumor lines. Tumor growth retardation depended on the amount of radioactivity injected and nonradioactive estradiol was without any salutary effect on tumor size or host survival. Neither survival times nor tumor growth rate were altered by radioactive [3H]progesterone. The underlying mechanism(s) is (are) referable to ionizing radiation by the specific carrier estradiol or to an isotope effect of [3H]estradiol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7046975     DOI: 10.1007/bf00292866

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  SERUM PROPERDIN IN TUMOR-BEARING MICE. I. COMPARISON WITH NATURAL AND IMMUNE ANTIBODIES.

Authors:  E E SCHWARTZ; S WINSTEN
Journal:  Cancer Res       Date:  1964-06       Impact factor: 12.701

2.  Statistics for disinterested scientists.

Authors:  J A Zivin; J J Bartko
Journal:  Life Sci       Date:  1976-01-01       Impact factor: 5.037

Review 3.  Early stages in estrogen control of gene expression and its derangement in cancer.

Authors:  F Bresciani; E Nola; V Sica; G A Puca
Journal:  Fed Proc       Date:  1973-11

4.  Inhibition of the growth of mouse polyoma tumors by lymph node fragments from specifically immunized rats.

Authors:  H F Jeejeebhoy; A G Rabbat
Journal:  Cancer Res       Date:  1969-05       Impact factor: 12.701

5.  Differences in growth and morphology between the spontaneous C3H mammary carcinoma in the mouse and its syngeneic transplants.

Authors:  J A McCredie; W R Inch; R M Sutherland
Journal:  Cancer       Date:  1971-03       Impact factor: 6.860

6.  Effect of ovariectomy and adrenalectomy on luteinizing hormone-releasing hormone in pituitary stalk blood from female rats.

Authors:  N M Sherwood; G Fink
Journal:  Endocrinology       Date:  1980-01       Impact factor: 4.736

7.  Effect of castration and steroid replacement on immunoreactive gonadotropin-releasing hormone in hypothalamus and preoptic area.

Authors:  D S Gross
Journal:  Endocrinology       Date:  1980-05       Impact factor: 4.736

8.  Modulation of hypothalamic luteinizing hormone-releasing hormone levels by intracranial and subcutaneous implants of gonadal steroids in castrated rats: effects of androgen and estrogen antagonists.

Authors:  P S Kalra; S P Kalra
Journal:  Endocrinology       Date:  1980-01       Impact factor: 4.736

9.  Combined treatment with radioestradiol-lucanthone in mouse C3HBA mammary adenocarcinoma and with estradiol-lucanthone in an estrogen bioassay.

Authors:  J Padawer; G Rettura; B Thysen; M Gatz; E Seifter
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-03       Impact factor: 7.038

10.  Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.

Authors:  R I Nicholson; P V Maynard
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.